Follow
William E. Fantegrossi
William E. Fantegrossi
Associate Professor, Department of Pharmacology and Toxicology, UAMS
Verified email at uams.edu - Homepage
Title
Cited by
Cited by
Year
The behavioral pharmacology of hallucinogens
WE Fantegrossi, KS Murnane, CJ Reissig
Biochemical pharmacology 75 (1), 17-33, 2008
2782008
Distinct pharmacology and metabolism of K2 synthetic cannabinoids compared to Δ9-THC: mechanism underlying greater toxicity?
WE Fantegrossi, JH Moran, A Radominska-Pandya, PL Prather
Life sciences 97 (1), 45-54, 2014
2682014
Phase I hydroxylated metabolites of the K2 synthetic cannabinoid JWH-018 retain in vitro and in vivo cannabinoid 1 receptor affinity and activity
LK Brents, EE Reichard, SM Zimmerman, JH Moran, WE Fantegrossi, ...
PloS one 6 (7), e21917, 2011
2442011
Quantitative measurement of JWH-018 and JWH-073 metabolites excreted in human urine
CL Moran, VH Le, KC Chimalakonda, AL Smedley, FD Lackey, SN Owen, ...
Analytical chemistry 83 (11), 4228-4236, 2011
1962011
Baths salts, spice, and related designer drugs: the science behind the headlines
MH Baumann, E Solis, LR Watterson, JA Marusich, WE Fantegrossi, ...
Journal of neuroscience 34 (46), 15150-15158, 2014
1822014
Monohydroxylated metabolites of the K2 synthetic cannabinoid JWH-073 retain intermediate to high cannabinoid 1 receptor (CB1R) affinity and exhibit neutral antagonist to …
LK Brents, A Gallus-Zawada, A Radominska-Pandya, T Vasiljevik, ...
Biochemical pharmacology 83 (7), 952-961, 2012
1772012
3,4-Methylenedioxymethamphetamine (MDMA, "ecstasy") and its stereoisomers as reinforcers in rhesus monkeys: serotonergic involvement
WE Fantegrossi, T Ullrich, KC Rice, JH Woods, G Winger
Psychopharmacology 161 (4), 356-364, 2002
1692002
In vivo effects of abused ‘bath salt’constituent 3, 4-methylenedioxypyrovalerone (MDPV) in mice: drug discrimination, thermoregulation, and locomotor activity
WE Fantegrossi, BM Gannon, SM Zimmerman, KC Rice
Neuropsychopharmacology 38 (4), 563-573, 2013
1512013
MDMA use and neurocognition: a meta-analytic review
AD Kalechstein, R De La Garza, JJ Mahoney, WE Fantegrossi, TF Newton
Psychopharmacology 189, 531-537, 2007
1502007
Pharmacological characterization of the effects of 3, 4-methylenedioxymethamphetamine (" ecstasy") and its enantiomers on lethality, core temperature, and locomotor activity in …
WE Fantegrossi, T Godlewski, RL Karabenick, JM Stephens, T Ullrich, ...
Psychopharmacology 166, 202-211, 2003
1432003
Pharmacological characterization of the effects of 3, 4-methylenedioxymethamphetamine (" ecstasy") and its enantiomers on lethality, core temperature, and locomotor activity in …
WE Fantegrossi, T Godlewski, RL Karabenick, JM Stephens, T Ullrich, ...
Psychopharmacology 166, 202-211, 2003
1432003
Behavioral and neurochemical consequences of long-term intravenous self-administration of MDMA and its enantiomers by rhesus monkeys
WE Fantegrossi, WL Woolverton, M Kilbourn, P Sherman, J Yuan, ...
Neuropsychopharmacology 29 (7), 1270-1281, 2004
1192004
Pharmacological and toxicological effects of synthetic cannabinoids and their metabolites
S Tai, WE Fantegrossi
Neuropharmacology of New Psychoactive Substances (NPS) The Science Behind …, 2017
1182017
Forensic investigation of K2, Spice, and “bath salt” commercial preparations: a three-year study of new designer drug products containing synthetic cannabinoid, stimulant, and …
KA Seely, AL Patton, CL Moran, ML Womack, PL Prather, WE Fantegrossi, ...
Forensic science international 233 (1-3), 416-422, 2013
1172013
The value of nonhuman primates in drug abuse research.
EM Weerts, WE Fantegrossi, AK Goodwin
Experimental and clinical psychopharmacology 15 (4), 309, 2007
1162007
Synthetic pot: not your grandfather’s marijuana
BM Ford, S Tai, WE Fantegrossi, PL Prather
Trends in pharmacological sciences 38 (3), 257-276, 2017
1122017
A comparison of the physiological, behavioral, neurochemical and microglial effects of methamphetamine and 3, 4-methylenedioxymethamphetamine in the mouse
WE Fantegrossi, JR Ciullo, KT Wakabayashi, R De La Garza II, ...
Neuroscience 151 (2), 533-543, 2008
1072008
Synthetic cannabinoids: pharmacology, behavioral effects, and abuse potential
S Tai, WE Fantegrossi
Current addiction reports 1, 129-136, 2014
1052014
Hallucinogen-like actions of 5-methoxy-N, N-diisopropyltryptamine in mice and rats
WE Fantegrossi, AW Harrington, CL Kiessel, JR Eckler, RA Rabin, ...
Pharmacology Biochemistry and Behavior 83 (1), 122-129, 2006
1032006
Transient reinforcing effects of phenylisopropylamine and indolealkylamine hallucinogens in rhesus monkeys
WE Fantegrossi, JH Woods, G Winger
Behavioural pharmacology 15 (2), 149-157, 2004
1032004
The system can't perform the operation now. Try again later.
Articles 1–20